ArticleEcancermedicalscience2025
Clinicopathological prognostic factors for survival in patients with breast cancer: a retrospective study from a tertiary cancer centre from North-West India.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07130162 (Detection of Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein as Serum Biomarker for Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Detection of Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein as Serum Biomarker for Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Among women worldwide, breast cancer is the most prevalent malignancy. Understanding potential prognostic indicators is critical for selecting the optimal treatment modalities, evaluating the response and creating a follow-up plan. In this retrospective study, the clinical and pathological features of primary breast cancer patients who presented to the tertiary cancer centre in the past 10 years were retrospectively studied and analysed to assess their correlation with survival. Patients and methods: Histopathologically confirmed breast cancer patients presenting between January 2014 and December 2023 were included in this study. Clinical data and treatment details including the surgical procedure, chemotherapy and radiation treatment were collected from the medical records. The study utilised both univariate and multivariate Cox proportional hazards models to determine the most significant independent prognostic variables for overall survival (OS). Results: A total of 676 patients were treated for breast cancer in our centre between January 2014 and December 2023. The median age was 50 years. Three seventy nine patients (56.0%) presented with early breast cancer at the time of diagnosis while 272 patients (40.2%) had locally advanced breast cancer corresponding to clinical stage III. Twenty one (3.1%) patients presented with stage IV. In the univariate analysis, factors significantly associated with OS were stage at presentation, grade, positive lymph node status, number of positive lymph nodes, presence of lymphovascular space invasion (LVSI), presence of perinodal extension (PNE) and distant metastasis at presentation. On multivariate analysis, grade of tumor, LVSI and PNE were significant factors affecting survival outcome. Conclusion: Clinical stage at presentation, tumour grade, lymph node status, presence of LVSI, PNE and tumour grade were the prognostic variables substantially associated with survival. A comprehensive approach that includes early detection and appropriate treatment modalities tailored to individual patient characteristics is essential for optimising survival outcomes in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.